Artificial intelligence (AI) corporations Anthropic is accelerating its expansion into healthcare and preparations for an initial public offering (IPO) by bringing the Novartis chief executive officer (CEO) onto its board.
Anthropic said on the 14th (local time) that the independent body Long-Term Benefit Trust (LTBT) appointed Novartis CEO Vasant Narasimhan as a new director.
Narasimhan, a physician-scientist, is an expert in public health and medicine and a member of the U.S. National Academy of Medicine. Anthropic is expected to strengthen the use of AI in healthcare and the life sciences through this appointment.
Anthropic has recently expanded partnerships with global drugmakers such as Eli Lilly and Novo Nordisk and increased investment in healthcare, including acquiring the life-science startup Coefficient Bio.
With this personnel move, the structure under which the LTBT appoints a board majority has been completed. The LTBT is an independent body composed of five Commissioners with no financial interests and holds the authority to appoint and dismiss a majority of directors.
The current board consists of seven members, including siblings Dario and Daniela Amodei and representatives from investors, and Netflix co-founder Reed Hastings is also participating.
Meanwhile, Anthropic is said to be planning to unveil as early as this week its next-generation AI model "Claude Opus 4.7" and an AI-based design tool.